The Latest Cardiac and Vascular News
Study Presented at the 71st Annual American College of Cardiology Meeting Oak Ridge, TN, April 06, 2022 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data from Duke Heart that was presented on April 2nd at the American College of Cardiology (ACC) 71st Scientific Sessions […]
In subjects with PAH, transition from Tyvaso® to Tyvaso DPI™ demonstrated safety and tolerability with significant improvements in six-minute walk distance, device preference and satisfaction, and patient reported outcomes Tyvaso DPI safety confirmed through 51 weeks of optional extension phase data with no study drug-related serious adverse events FDA action on […]
Combined Company to Spearhead Transformation of Cardiovascular Disease Drug Discovery and Development BOSTON, April 5, 2022 /PRNewswire/ — Valo Health, LLC (“Valo”), announced today the acquisition of TARA Biosystems, Inc. (“TARA”), a New York City-based cardiovascular disease biotechnology company, creating the first of its kind vertically integrated cardiovascular drug discovery and development platform. The combination of TARA’s proprietary […]
First clinical trial to evaluate the safety & efficacy of RT234 on exercise parameters assessed by Cardiopulmonary Exercise Testing (CPET) PALO ALTO, Calif., April 5, 2022 /PRNewswire/ — Respira Therapeutics, Inc. a clinical-stage company developing inhaled therapeutics for cardiopulmonary diseases that improve patient outcomes through enhanced drug targeting to the small airways of […]
SAN FRANCISCO, CA and TORONTO, ON, April 05, 2022 (GLOBE NEWSWIRE) — Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: CLAZF) (the “Company” or “Claritas“) today announced that the Australian Human Research Ethics Committee has approved the Company’s submission for the Phase 1 clinical study of R-107 to be conducted […]
Largest ever real-world analysis of Cardiac Implantable Electronic Device (CIED) infection treatment presented at the American College of Cardiology’s 71st Annual Scientific Session [1] demonstrates that approximately 4 in 5 patients are not treated according to HRS/EHRA Class I guidelines [2,3] for CIED infection In the absence of guideline-driven care, […]
– ETESIAN Phase 2b study of ION449 (AZD8233) met its primary and secondary endpoints; ION449 was generally well tolerated – ION449 demonstrated potential best-in-class efficacy profile for a self-administered subcutaneous monthly dose regimen – Study findings warrant further clinical development of ION449 for patients with hypercholesterolemia at high cardiovascular risk CARLSBAD, Calif., April 4, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. […]
Clinical Study Confirms Ability to Identify Lung Congestion with Medical-Grade Accuracy TEL AVIV, Israel and WASHINGTON, D.C. – April 4, 2022 – Donisi Health, a MedTech company working to disrupt the readmission cycle of congestive heart failure (CHF) patients, announced results of a clinical study demonstrating the efficacy of its […]
Medtronic adds to its robust clinical program with long-term data demonstrating the continued blood pressure lowering effect of the Symplicity renal denervation procedure Medtronic also completes enrollment in the SPYRAL HTN-ON MED trial DUBLIN and WASHINGTON, April 4, 2022 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced long-term data […]
No Effect of Omecamtiv Mecarbil On Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction in METEORIC-HF Healthcare Resource Utilization and Cost Analysis from GALACTIC-HF Demonstrate Treatment with Omecamtiv Mecarbil Led to 19% Cost Reduction Per Patient in Key Subgroup Additional Results from GALACTIC-HF Indicate Treatment with Omecamtiv […]
